Independent prognostic effect of co-morbidity in lymphoma patients: Results of the population-based Eindhoven Cancer Registry

The prevalence of co-morbidity among elderly lymphoma patients is associated with a decrease in the use of chemotherapy. This study assessed the independent prognostic effect of co-morbidity in 1551 unselected lymphoma patients, diagnosed between 1995 and 2001 in the area of the population-based Ein...

Full description

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 2005-05, Vol.41 (7), p.1051-1057
Main Authors: van Spronsen, D.J., Janssen-Heijnen, M.L.G., Lemmens, V.E.P.P., Peters, W.G., Coebergh, J.W.W.
Format: Article
Language:English
Subjects:
Adult
Age Distribution
Aged
Aged, 80 and over
Biological and medical sciences
Co-morbidity
Comorbidity
Elderly
Female
Follow-Up Studies
Hodgkin Disease - drug therapy
Hodgkin Disease - mortality
Humans
Lymphoma
Lymphoma, Non-Hodgkin - drug therapy
Lymphoma, Non-Hodgkin - mortality
Male
Medical sciences
Middle Aged
Netherlands - epidemiology
Pharmacology. Drug treatments
Prevalence
Prognosis
Proportional Hazards Models
Registries
Survival
Survival Analysis
Survival Rate
Treatment
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The prevalence of co-morbidity among elderly lymphoma patients is associated with a decrease in the use of chemotherapy. This study assessed the independent prognostic effect of co-morbidity in 1551 unselected lymphoma patients, diagnosed between 1995 and 2001 in the area of the population-based Eindhoven Cancer Registry. The prevalence of serious co-morbidity was 58% for patients with Hodgkin’s disease (HD) who were over 60 years of age and 66% for patients with non-Hodgkin’s lymphoma (NHL) who were over 60 years of age. The administration of chemotherapy declined in the presence of co-morbidity for elderly patients with early-stage HD and elderly patients with aggressive NHL. Co-morbidity was associated with a 10–20% decline in 5-year survival. Whether less frequent application of chemotherapy in the presence of co-morbidity is justified as far as complications, prognosis and quality of life are concerned requires further investigation.
ISSN:0959-8049
1879-0852
DOI:10.1016/j.ejca.2005.01.010